Primary Ovarian Insufficiency in Women With Addison’s Disease

• Published in: The journal of clinical endocrinology and metabolism 2021-07, Vol.106 (7), p.e2656-e2663
• Main Authors: Vogt, Elinor C, Breivik, Lars, Røyrvik, Ellen C, Grytaas, Marianne, Husebye, Eystein S, Øksnes, Marianne
• Format: Article
• Language: English
• Subjects: Addison Disease - complications; Addison Disease - genetics; Addison Disease - immunology; Adult; Autoantibodies; Autoantibodies - blood; Autoantibodies - immunology; Autoimmune diseases; Autoimmunity; Cholesterol Side-Chain Cleavage Enzyme - immunology; Clinical s; Enzymes; Female; Fertility; Genomes; Genomics; Hormone replacement therapy; Hormone Replacement Therapy - statistics & numerical data; Hormone therapy; Humans; Menopause; Menopause, Premature - blood; Menopause, Premature - genetics; Menopause, Premature - immunology; Menstruation; Norway - epidemiology; Ovaries; Polymorphism, Single Nucleotide; Population studies; Predictive Value of Tests; Prevalence; Primary Ovarian Insufficiency - epidemiology; Primary Ovarian Insufficiency - genetics; Primary Ovarian Insufficiency - immunology; Registries; Single nucleotide polymorphisms; Single-nucleotide polymorphism; Womens health
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/clinem/dgab140

Abstract Context Primary ovarian insufficiency (POI) is defined by menopause before 40 years of age. POI prevalence is higher among women with autoimmune Addison’s disease (AAD) than in the general population, but their clinical characteristics are insufficiently studied. Objective To assess the prevalence of POI in a large cohort of women with AAD and describe clinical, immunological, and genetic characteristics. Methods An observational population-based cohort study of the Norwegian National Addison Registry. The Norwegian Prescription Database was used to assess prescription of menopausal hormone replacement therapy (HRT). A total of 461 women with AAD were studied. The primary outcome measure was prevalence of POI. Secondary outcomes were clinical characteristics, autoantibodies, and genome-wide single nucleotide polymorphism variation. Results The prevalence of POI was 10.2% (47/461) and one-third developed POI before 30 years of age. POI preceded or coincided with AAD diagnosis in more than half of the women. The prevalence of concomitant autoimmune diseases was 72%, and AAD women with POI had more autoantibodies than AAD women without (≥2 autoantibodies in 78% vs 25%). Autoantibodies against side-chain cleavage enzyme (SCC) had the highest accuracy with a negative predictive value for POI of 96%. HRT use was high compared to the age adjusted normal population (11.3 % vs 0.7%). Conclusion One in 10 women with AAD have POI. Autoantibodies against SCC are the most specific marker for autoimmune POI. We recommend testing women with AAD